Q2 2024 EPS Estimates for Kiora Pharmaceuticals, Inc. (NASDAQ:KPRX) Decreased by HC Wainwright

Kiora Pharmaceuticals, Inc. (NASDAQ:KPRX) – Analysts at HC Wainwright reduced their Q2 2024 EPS estimates for shares of Kiora Pharmaceuticals in a research note issued to investors on Monday, May 20th. HC Wainwright analyst Y. Chen now expects that the company will post earnings of ($0.09) per share for the quarter, down from their prior forecast of ($0.08). HC Wainwright has a “Buy” rating and a $2.00 price objective on the stock. The consensus estimate for Kiora Pharmaceuticals’ current full-year earnings is $0.11 per share. HC Wainwright also issued estimates for Kiora Pharmaceuticals’ Q4 2024 earnings at ($0.08) EPS and FY2024 earnings at $0.15 EPS.

Kiora Pharmaceuticals Price Performance

Kiora Pharmaceuticals stock opened at $0.54 on Wednesday. Kiora Pharmaceuticals has a fifty-two week low of $0.45 and a fifty-two week high of $2.24. The firm has a fifty day moving average price of $0.56 and a two-hundred day moving average price of $0.58.

Institutional Inflows and Outflows

A hedge fund recently bought a new stake in Kiora Pharmaceuticals stock. Rosalind Advisors Inc. bought a new position in shares of Kiora Pharmaceuticals, Inc. (NASDAQ:KPRX) in the first quarter, according to the company in its most recent Form 13F filing with the SEC. The fund bought 2,300,000 shares of the company’s stock, valued at approximately $1,624,000. Kiora Pharmaceuticals comprises 1.5% of Rosalind Advisors Inc.’s portfolio, making the stock its 22nd largest position. Rosalind Advisors Inc. owned 8.76% of Kiora Pharmaceuticals at the end of the most recent quarter. 76.97% of the stock is owned by hedge funds and other institutional investors.

Kiora Pharmaceuticals Company Profile

Kiora Pharmaceuticals, Inc, a clinical-stage specialty pharmaceutical company, develops and commercializes therapies for the treatment of ophthalmic diseases in the United States. Its lead product is KIO-301, a potential vision-restoring small molecule, which is in Phase 1b clinical trial that acts as a photoswitch to restore vision in patients with inherited and age-related degenerative retinal diseases.